Episodes

  • Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

    Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer
    Jan 3 2025
    Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.
    Show more Show less
    2 hrs and 1 min
  • Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer

    Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer
    Dec 23 2024
    Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.
    Show more Show less
    1 hr and 31 mins
  • 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2

    5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2
    Dec 16 2024
    Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.
    Show more Show less
    12 mins
  • Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 

    Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 
    Dec 5 2024
    Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.
    Show more Show less
    1 hr
  • 5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

    5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
    Nov 26 2024
    Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.
    Show more Show less
    11 mins
  • Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities

    Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
    Nov 19 2024
    Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
    Show more Show less
    57 mins
  • Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer

    Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast Cancer
    Nov 16 2024
    Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
    Show more Show less
    1 hr and 4 mins
  • Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

    Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
    Nov 1 2024
    Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
    Show more Show less
    59 mins